Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors

A. Sorf, S. Sucha, A. Morell, E. Novotna, F. Staud, A. Zavrelova, B. Visek, V. Wsol, M. Ceckova,

. 2020 ; 12 (6) : . [pub] 20200616

Language English Country Switzerland

Document type Journal Article

Grant support
PRIMUS/20/MED/010 Univerzita Karlova v Praze
SVV/260-414 Univerzita Karlova v Praze
grant No. 20-20414Y Grantová Agentura České Republiky
EFSA-CDN (grant No. CZ.02.1.01/0.0/0.0/16_019/0000841) Ministerstvo Školství, Mládeže a Tělovýchovy

Pharmacotherapy of acute myeloid leukemia (AML) remains challenging, and the disease has one of the lowest curability rates among hematological malignancies. The therapy outcomes are often compromised by the existence of a resistant AML phenotype associated with overexpression of ABCB1 and ABCG2 transporters. Because AML induction therapy frequently consists of anthracycline-like drugs, their efficiency may also be diminished by drug biotransformation via carbonyl reducing enzymes (CRE). In this study, we investigated the modulatory potential of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib on AML resistance using peripheral blood mononuclear cells (PBMC) isolated from patients with de novo diagnosed AML. We first confirmed inhibitory effect of the tested drugs on ABCB1 and ABCG2 in ABC transporter-expressing resistant HL-60 cells while also showing the ability to sensitize the cells to cytotoxic drugs even as no effect on AML-relevant CRE isoforms was observed. All tested CDK4/6 inhibitors elevated mitoxantrone accumulations in CD34+ PBMC and enhanced accumulation of mitoxantrone was found with abemaciclib and ribociclib in PBMC of FLT3-ITD- patients. Importantly, the accumulation rate in the presence of CDK4/6 inhibitors positively correlated with ABCB1 expression in CD34+ patients and led to enhanced apoptosis of PBMC in contrast to CD34- samples. In summary, combination therapy involving CDK4/6 inhibitors could favorably target multidrug resistance, especially when personalized based on CD34- and ABCB1-related markers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019037
003      
CZ-PrNML
005      
20201123124600.0
007      
ta
008      
201103s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers12061596 $2 doi
035    __
$a (PubMed)32560251
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Sorf, Ales $u Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
245    10
$a Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors / $c A. Sorf, S. Sucha, A. Morell, E. Novotna, F. Staud, A. Zavrelova, B. Visek, V. Wsol, M. Ceckova,
520    9_
$a Pharmacotherapy of acute myeloid leukemia (AML) remains challenging, and the disease has one of the lowest curability rates among hematological malignancies. The therapy outcomes are often compromised by the existence of a resistant AML phenotype associated with overexpression of ABCB1 and ABCG2 transporters. Because AML induction therapy frequently consists of anthracycline-like drugs, their efficiency may also be diminished by drug biotransformation via carbonyl reducing enzymes (CRE). In this study, we investigated the modulatory potential of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib on AML resistance using peripheral blood mononuclear cells (PBMC) isolated from patients with de novo diagnosed AML. We first confirmed inhibitory effect of the tested drugs on ABCB1 and ABCG2 in ABC transporter-expressing resistant HL-60 cells while also showing the ability to sensitize the cells to cytotoxic drugs even as no effect on AML-relevant CRE isoforms was observed. All tested CDK4/6 inhibitors elevated mitoxantrone accumulations in CD34+ PBMC and enhanced accumulation of mitoxantrone was found with abemaciclib and ribociclib in PBMC of FLT3-ITD- patients. Importantly, the accumulation rate in the presence of CDK4/6 inhibitors positively correlated with ABCB1 expression in CD34+ patients and led to enhanced apoptosis of PBMC in contrast to CD34- samples. In summary, combination therapy involving CDK4/6 inhibitors could favorably target multidrug resistance, especially when personalized based on CD34- and ABCB1-related markers.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sucha, Simona $u Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
700    1_
$a Morell, Anselm $u Department of Biochemical Sciences, Charles University, Faculty of Pharmacy, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
700    1_
$a Novotna, Eva $u Department of Biochemical Sciences, Charles University, Faculty of Pharmacy, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
700    1_
$a Staud, Frantisek $u Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
700    1_
$a Zavrelova, Alzbeta $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Sokolska 581, 50005 Hradec Kralove, Czech Republic.
700    1_
$a Visek, Benjamin $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Sokolska 581, 50005 Hradec Kralove, Czech Republic.
700    1_
$a Wsol, Vladimir $u Department of Biochemical Sciences, Charles University, Faculty of Pharmacy, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
700    1_
$a Ceckova, Martina $u Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 6 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32560251 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20201123124558 $b ABA008
999    __
$a ind $b bmc $g 1585817 $s 1109235
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 6 $e 20200616 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a PRIMUS/20/MED/010 $p Univerzita Karlova v Praze
GRA    __
$a SVV/260-414 $p Univerzita Karlova v Praze
GRA    __
$a grant No. 20-20414Y $p Grantová Agentura České Republiky
GRA    __
$a EFSA-CDN (grant No. CZ.02.1.01/0.0/0.0/16_019/0000841) $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20201103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...